Observational studyAmerican journal of respiratory and critical care medicine2020
Females with Cystic Fibrosis Demonstrate a Differential Response Profile to Ivacaftor Compared with Males.
Observational study in American journal of respiratory and critical care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Article
- Remote analysis and management of sweat biomarkers using a wearable microfluidic sticker in adult cystic fibrosis patients.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Sex disparities in cystic fibrosis in the era of highly effective modulator treatment.BMC pulmonary medicine · 2025Review
- Toward a Systematic Assessment of Sex Differences in Cystic Fibrosis.Journal of personalized medicine · 2023Article
- Characterizing CFTR modulated sweat chloride response across the cf population: Initial results from the CHEC-SC study.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2023Article
- The gut-lung axis in the CFTR modulator era.Frontiers in cellular and infection microbiology · 2023Review
- Spirometric and anthropometric improvements in response to elexacaftor/tezacaftor/ivacaftor depending on age and lung disease severity.Frontiers in pharmacology · 2023Article
- Dual CFTR modulator therapy efficacy in the real world: lessons for the future.ERJ open research · 2022Article
- Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.American journal of respiratory and critical care medicine · 2022Observational
- Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators.Journal of personalized medicine · 2021Article
- Sex differences in treatment patterns in cystic fibrosis pulmonary exacerbations.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2021Article
- Update in Pediatrics 2020.American journal of respiratory and critical care medicine · 2021Article
- The Human Microbiome, an Emerging Key-Player in the Sex Gap in Respiratory Diseases.Frontiers in medicine · 2021Review
- Sex disparities in cystic fibrosis: review on the effect of female sex hormones on lung pathophysiology and outcomes.ERJ open research · 2021Review
- The PROSPECT Is Bright for CFTR Modulators.Annals of the American Thoracic Society · 2021Article
- Caring for gender diverse youth with cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2020Article
- The era of CFTR modulators: improvements made and remaining challenges.Breathe (Sheffield, England) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.